Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by duskwon Nov 30, 2011 3:07pm
302 Views
Post# 19280092

Options - Message to the BOD

Options - Message to the BODMessage to the board of directors should be clear - DO NOT ENRICH EXECUTIVES with cheap options. There should be no reward of a low strike price for brining the company's share price to an all-time low.
Instead, any stock options issued should be set AT THE HIGHEST trading price for the year. That will give management a significant incentive to drive the stock price back up, and keep it high. With the current model: Q1/Q2 profit, Q3/Q4 loss, it is inevitable that the share price will be depressed around the end of year and options issuance.
This matter needs to be addressed.
Anyone interested in creating an official petition to the board of directors for such a move? Private msg me.
Bullboard Posts